van Tiel F, Harbers M M, Terporten P H W, van Boxtel R T C, Kessels A G, Voss G B W E, Schouten H C
Maastricht Infection Center, Department of Medical Microbiology, University; Hospital Maastricht, Maastricht, the Netherlands.
Ann Oncol. 2007 Jun;18(6):1080-4. doi: 10.1093/annonc/mdm082. Epub 2007 Mar 16.
The purpose of this randomized, controlled pilot study is to address the question whether normal hospital diet (NHD) is safe when compared with low-bacterial diet (LBD) given to prevent infections in cytopenic patients who receive antimicrobial prophylaxis (AP).
The patients were randomized into two groups: one group to receive AP and LBD, the other to receive the same AP and NHD. The primary outcome parameter is colonization of the digestive tract with aerobic gram-negative bacilli and yeasts. Secondary outcome parameters were infections and total societal costs.
No statistically significant differences between treatment groups were observed regarding the primary outcome parameter, gut colonization by yeasts or gram-negative bacilli, or infections, use of antimicrobials, days with fever and total societal costs.
On the basis of the results of this pilot study, NHD appears to be as safe as LBD in patients with chemotherapy-induced cytopenia. Furthermore, the results indicate that LBD may offer no additional benefit as an infection preventive measure to the measures already implemented, such as AP. Thus, a larger randomized study, powered adequately to determine noninferiority of NHD to LBD is warranted and safe to be carried out.
这项随机对照试验性研究的目的是探讨在接受抗菌药物预防(AP)的血细胞减少患者中,为预防感染而给予的普通医院饮食(NHD)与低菌饮食(LBD)相比是否安全。
将患者随机分为两组:一组接受AP和LBD,另一组接受相同的AP和NHD。主要结局参数是消化道需氧革兰氏阴性杆菌和酵母菌的定植情况。次要结局参数是感染情况和社会总成本。
在主要结局参数、酵母菌或革兰氏阴性杆菌的肠道定植、感染、抗菌药物使用、发热天数和社会总成本方面,各治疗组之间未观察到统计学上的显著差异。
基于这项试验性研究的结果,在化疗引起的血细胞减少患者中,NHD似乎与LBD一样安全。此外,结果表明,作为一种感染预防措施,LBD可能不会比已实施的措施(如AP)带来更多益处。因此,有必要开展一项规模更大的随机研究,以充分验证NHD不劣于LBD,并且这样做是安全的。